Global Vaccine Market Forecast to 2012

Summary

Vaccines have emerged as one of the most lucrative segment in the global pharmaceutical industry. With a projected CAGR of over 13% during 2009-2012, the industry will emerge as the fastest growing therapy area. The US and Europe represent the two largest vaccine markets in the world and will continue experiencing healthy growth rate in future.

As per our researchGlobal Vaccine Market Forecast to 2012', the segment of pediatric vaccines presently dominates the global vaccine market; however, adult vaccine segments will define the future growth directions. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers.

Owing to lower margins and the mature nature of these markets, the basic and enhanced pediatric markets are expected to show insignificant growth in future. On the other hand, launch of a number of new vaccines will make the addiction, cancer and proprietary pediatrics/adolescent vaccine market highly dynamic. On a whole, the global vaccine market is expected to register revenues in excess of US$ 34 Billion by 2012.

Our analysis of the competitive landscape of the global vaccine market shows a highly concentrated structure, with the top four players accounting for around 74% of the total market in 2008.

Our report gives an extensive and objective analysis on the global vaccine market. It investigates both the past and current trends in the vaccine market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of vaccines, both in the market as well as in the developing stage. Based on various present and future indicators, the report evaluates the prospects of various vaccine segments. The report can, thus, prove critical to manufacturers/investors preparing to enter the vaccine market.

The report includes forecast till 2012 on:

*Global Vaccine Revenues
*Basic Pediatrics Vaccine Revenues
*Enhanced Pediatrics Vaccine Revenues
*Proprietary Pediatrics/Adolescent Vaccine Revenues
*Adult Vaccine Revenues
*Influenza Vaccine Revenues
*Cancer Vaccines Revenues
*Share of Key Players in Vaccine Market
*Revenues of Key Vaccine Brands

A section on the market landscape has also been included in the report to give a category-wise overview of the key players, including Sanofi-Aventis, GlaxoSmithKline, Merk & Co., Inc, Novartis and Wyeth, operating in the global vaccine market.

Table of Contents

1. Analyst View
2. The Global Vaccine Market
    2.1 Introduction
    2.2 Market Opportunity Assessment
3. Critical Success and Risk Factors
    3.1 Critical Success Factors
          3.1.1 Disease Prevention
          3.1.2 Higher Margins
          3.1.3 Support from Government and NGOs
          3.1.4 Blockbuster Potential of New Vaccines
    3.2 Critical Risk Factors
          3.2.1 Huge R&D Cost
          3.2.2 Immunization Safety
          3.2.3 Inequality in Distribution
          3.2.4 Lack of Infrastructure for Trials and Manufacturing
          3.2.5 Effective Vaccine Design
          3.2.6 Vaccine Supply
4. Major Vaccine Segments
    4.1 Basic Pediatrics
    4.2 Enhanced Pediatrics
    4.3 Proprietary Pediatrics
    4.4 Adult Vaccines
          4.4.1 Cancer Vaccines
          4.4.2 Addiction Vaccines
          4.4.3 Influenza Vaccines
5. Major Pediatric Vaccines
    5.1 Pneumococcal Vaccines
    5.2 Polio Vaccines
    5.3 Varicella Vaccines
    5.4 Meningitis Vaccines
    5.5 Rotavirus Vaccines
    5.6 DTP Vaccines
    5.7 Measles, Mumps & Rubella (MMR) Vaccines
    5.8 Tuberculosis Vaccines
6. Major Adult/Travel & Therapeutic Vaccines
    6.1 Hepatitis B Vaccines
    6.2 Malaria Vaccines
    6.3 Japanese Encephalitis Vaccines
    6.4 Ebola Vaccines
    6.5 Cervical Cancer Vaccines
    6.6 Typhoid Vaccines
    6.7 West Nile Vaccines
    6.8 HIV Vaccines
7. Key Geographical Markets
    7.1 US
    7.2 Europe
    7.3 China
    7.4 India
    7.5 Japan
    7.6 Brazil
8. Competitive Landscape to 2012
    8.1 Revenues and Growth of Key Players
    8.2 Revenues and Growth of Key Vaccine Brands
    8.3 Key Mergers and Acquisitions
    8.4 Major Categories of Players
          8.4.1 Vaccine Majors
          8.4.2 Vaccine-focused Biotech Companies
          8.4.3 Domestic-focused Vaccine Companies
    8.5 Key Company Profiles
          8.5.1 Sanofi-Aventis
          8.5.2 GlaxoSmithKline Plc.
          8.5.3 Merck & Co., Inc.
          8.5.4 Novartis
          8.5.5 Wyeth

List of Figures:

Figure 2-1: Vaccines Horizon (1960 to 2010)
Figure 2-2: Global-Vaccine Market by Player (%), 2008
Figure 2-3: Global-Vaccine Market by Region (%), 2008
Figure 2-4: Global-Forecast for Vaccine Market (Billion US$), 2009-2012
Figure 3-1: Global-Mortality and Morbidity of Diseases Preventable by Vaccine (¡®000)
Figure 3-2: Global-Profit Margin of Vaccines, Generics and Branded Drugs (%), 2007
Figure 3-3: Global-Vaccine Market by Source of Funding (%), 2005 to 2010
Figure 3-4: Global-Prevnar Sales (Billion US$), 2007 & 2008
Figure 3-5: Global-Gardasil Sales (Billion US$), 2007 & 2008
Figure 3-6: Global-Dose Consumption and Revenue by Regional Income (%), 2005
Figure 4-1: Global-Vaccine Market by Segment (%), 2007 & 2008
Figure 4-2: Global-Forecast for Vaccine Market by Segment (%), 2009-2012
Figure 4-3: Global-Basic Pediatric Vaccine Market (Million US$), 2006-2008
Figure 4-4: Global-Forecast for Basic Pediatric Vaccine Market (Million US$), 2009-2012
Figure 4-5: Global-Enhanced Pediatric Vaccine Market (Million US$), 2006-2008
Figure 4-6: Global-Forecast for Enhanced Pediatric Vaccine Market (Million US$), 2009-2012
Figure 4-7: Global-Proprietary Pediatric Vaccine Market (Million US$), 2006-2008
Figure 4-8: Global-Forecast for Proprietary Pediatric Vaccine Market (Million US$), 2009-2012
Figure 4-9: Global-Share of Adult Vaccine Sales in Vaccine Market (2006 & 2007)
Figure 4-10: Global-Adult Vaccine Market (Billion US$), 2006-2008
Figure 4-11: Global-Forecast for Adult Vaccine Market (Billion US$), 2009-2012
Figure 4-12: Global-Cancer Vaccine Market (Million US$), 2007, 2008 & 2012
Figure 4-13: Global-Number of Cancer Vaccines in Various Phases of Clinical Developments by Type (Aug 2005)
Figure 4-14: Global-Forecast for Addiction Vaccine Market (Million US$), 2009-2012
Figure 4-15: Global-Influenza Vaccine Market (Billion US$), 2009-2012
Figure 5-1: Global-Pipeline for Pneumococcal Vaccines
Figure 5-2: Global-Pneumococcal Vaccine Market (Million US$), 2007 & 2012
Figure 5-3: Global-Number of Polio Incidences (2006-2008)
Figure 5-4: Global-Countries with Maximum Number of Polio Incidences (2008)
Figure 5-5: Global-Polio Vaccine Market (Million US$), 2004 & 2011
Figure 5-6: Global-Varicella Vaccine Market (Million US$), 2007 & 2008
Figure 5-7: Global-Forecast for Meningitis Vaccine Demand for Epidemic Response (Million Doses) 2009-2012
Figure 5-8: US & Europe-Meningitis Vaccines Market Potential (Million)
Figure 5-9: Global-Forecast for Meningitis Vaccine Market (Million US$), 2009 & 2010
Figure 5-10: Global-Rotavirus Vaccine Market (Million US$), 2007 & 2010
Figure 5-11: Global-Forecast for Rotavirus Vaccine Market by Region (%), 2010
Figure 5-12: Global-Number of Diphtheria Incidences by Region (2007)
Figure 5-13: Global-Number of Pertussis Incidences by Region (2007)
Figure 5-14: Global-Number of nTetanus Incidences by Region (2007)
Figure 5-15: Global-Number of tTetanus Incidences by Region (2007)
Figure 5-16: Global-DTP Combos Market by Player (%), 2004
Figure 5-17: Global-Number of Measles Incidences by Region (2007)
Figure 5-18: Global-Number of Mumps Incidences by Region (2007)
Figure 5-19: Global-Number of Rubella Incidences by Region (2007)
Figure 5-20: Global-Number of Tuberculosis Incidences by Region (¡®000), 2007
Figure 6-1: Global-Hepatitis B Surface Antigen Prevalence (%), 2006
Figure 6-2: Global-Hepatitis B Vaccine Market (Billion US$), 2009-2012
Figure 6-3: Global-R&D Investment in AIDS Vaccine Development (Million US$), 2006-2008
Figure 6-4: Global-Sources for Funding in HIV Vaccine R&D (%), 2007
Figure 6-5: Global -HIV Funding Allocation by Category (%), 2007
Figure 7-1: Global-Vaccine Market by Region (%), 2008
Figure 7-2: Global-Forecast for Vaccine Market by Region (%), 2012
Figure 7-3: Global-Sales Split of Major Vaccine Players by Region (%), 2004
Figure 7-4: US-Vaccine Market (Billion US$), 2008-2012
Figure 7-5: US-Forecast for Pediatric Vaccine Market (Billion US$), 2009-2012
Figure 7-6: US-Hepatitis Vaccine Market (Billion US$), 2008-2012
Figure 7-7: US-Biodefense Vaccine Market (Million US$), 2008-2012
Figure 7-8: US-Influenza Vaccine Production and Consumption (Million Doses), 2004-2005 to 2007-2008
Figure 7-9: US-Influenza Vaccine Sales by Provider (%), 2007-2008
Figure 7-10: US-Influenza Vaccine Market (Million US$), 2008-2012
Figure 7-11: US-Travel Vaccine Market (Million US$), 2008-2012
Figure 7-12: US-Developmental Vaccine Market (Million US$), 2008-2012
Figure 7-13: Europe-Vaccine Market (Billion US$), 2007, 2008 & 2014
Figure 7-14: China-Vaccine Market (Million US$), 2006-2008
Figure 7-15: China-Forecast for Vaccine Market (Million US$), 2009-2012
Figure 7-16: China-Comparison of Annual Growth Rate of Vaccine Market with World (%)
Figure 7-17: China-Influenza Vaccine Market (Million US$) 2007 & 2008
Figure 7-18: China-Forecast for Influenza Vaccine Market (Million US$), 2009-2012
Figure 7-19: India-Share of Domestic Consumption and Exports in Vaccine Market (2007-08)
Figure 7-20: India-Share of Private Sector in Domestic Vaccine Market (2007-08)
Figure 7-21: India-Vaccine Market (Million US$), 2007-08 & 2008-09
Figure 7-22: India-Share of Major Players in Vaccine Market (2006-07)
Figure 7-23: India-Forecast for Vaccine Market (Million US$) 2009-10 to 2011-12
Figure 7-24: Japan-Vaccine Market (Million US$), 2007 & 2008
Figure 7-25: Japan-Influenza Vaccine Production (Million Doses), 2007-08 & 2008-09
Figure 7-26: Japan-Forecast for Vaccine Market (Million US$), 2009-2012
Figure 7-27: Brazil-Vaccine Market (Million BRL), 2007 & 2008
Figure 7-28: Brazil-Forecast for Vaccine Market (Million BRL), 2009-2012
Figure 7-29: Brazil-Share of Public and Private Sectors in Vaccine Market (2004)
Figure 8-1: Global-Share of Major Players in Vaccine Market (2007)
Figure 8-2: Global-Forecast for Share of Major Players in Vaccine Market (2012)
Figure 8-3: Global-Forecast for CAGR of Major Players in Vaccine Market (%), 2009 to 2012

List of Tables:

Table 2-1: Global-Top Selling Vaccines by Brand (Billion US$), 2008
Table 2-2: Global-Vaccine Sales of Top Companies (Million US$), 2008
Table 2-3: Recent Developments in Vaccine Market
Table 2-4: Global-Revenue from Major Therapy Areas (Million US$), 2007 & 2012
Table 3-1: Global-Number of Deaths due to Diphtheria Averted by Vaccines (¡®000), 2001
Table 3-2: Health Statistics in Developed and Developing Countries (%)
Table 4-1: US-Estimated Number of New Cancer Cases and Deaths (2008)
Table 4-2: Global-Five Year Relative Survival Rates by Stage of Cancer Diagnosis (%)
Table 4-3: Global-List of Launched and Under-development Cancer Vaccines by Indication
Table 5-1: Global-Pneumococcal Vaccine Supply
Table 6-1: Global-Number of HIV/AIDS Patients (2007)
Table 7-1: US-Influenza Vaccine Production (Million Doses), 2007-2008 & 2008-2009
Table 7-2: China-Number of Reported Cases of Diseases Preventable by Vaccine (2006 & 2007)
Table 7-3: China-Vaccine Classification
Table 7-4: China-Pediatric Vaccine Doses Requirement (Million)
Table 7-5: Brazil-Public and Private Sector Vaccine Market (Million BRL), 2000
Table 8-1: Global-Forecast for Top Launched Vaccine Brand Sales (Billion US$), 2009 & 2012
Table 8-2: Global-Forecast for Top Vaccine Brand Sales Under-development (Million US$), 2012
Table 8-3: Global-Key Mergers & Acquisitions in Vaccine Market (2005 to 2008)
Table 8-4: Global-Major Vaccine Companies (Segmentation by Revenue)

E-news Subscription

Register to receive email alerts of new market research reports and upcoming events in your industry

Subscribe Now!

Contact our customer services team

+86-10-58303339

+86-10-58303342

+86-10-58303470
(Global)

Research Category